Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Trifluoroacetic acid | HCID 6422 | — |
| Reactant | Tert-butyl 1-(4-(5-(4-isopropyl-5-(pyridin-2-yl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylate | HCID 66678392 | — |
| Solvent | Dichloromethane | HCID 6344 | — |
| Product | Trifluoroacetic acid | HCID 6422 | 7.8% |
| Product | 1-(4-(5-(4-Isopropyl-5-(pyridin-2-yl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylate | HCID 86661484 | — |
Reaction Steps
To a solution of the tert-butyl 1-(4-(5-(4-isopropyl-5-(pyridin-2-yl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylate in dichloromethane (0.5 mL) was added trifluoroacetic acid (0.5 mL), and the reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated and purified by preparative HPLC [Prep HPLC: Column: PHENOMENEX® S10 30×100 mm; Gradient time: 10 min; Flow rate=40 ml/min; Solvent A=10% MeOH—90% Water—0.1% TFA; Solvent B=90% MeOH—10% water—0.1% TFA; Start % B=20; Final % B=100.] to yield 1-(4-(5-(4-isopropyl-5-(pyridin-2-yl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylate, trifluoroacetic acid salt (2.03 mg, 3.47 mmol, 7.8%). The compound had an HPLC retention time=7.58 min.—Column: Xbridge Ph 3.5 u 4.6×150 mm; Gradient time: 12 min, hold for 3 minutes; Flow rate=2 ml/min; Solvent A=5% MeCN—95% Water—0.05% TFA; Solvent B=95% MeCN—5% water—0.05% TFA; Start % B=10; Final % B=100. LC-MS: M+1=446.3. 1H NMR (500 MHz, MeOD) δ ppm 1.44 (s, 3H), 1.46 (s, 3H), 3.68-3.76 (m, 1H), 4.19 (quin, J=7.15 Hz, 1H), 4.37-4.42 (m, 4H), 4.54 (s, 2H), 7.53 (ddd, J=7.49, 4.74, 1.24 Hz, 1H), 7.70 (d, J=8.25 Hz, 2H), 7.96-8.00 (m, 1H), 8.00-8.05 (m, 1H), 8.30 (d, J=8.25 Hz, 2H), and 8.79 (d, J=4.67 Hz, 1H).
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08404672B2 |
|---|
| Source dataset | uspto-grants-2013_03 |
|---|
| ORD ID | ord-66e64eb84e7045a1a1e57183f70f243b |
|---|
| Source note | uspto-grants-2013_03 |
|---|